Supernus Pharmaceuticals

Pioneering New Medicines in Neurology and Psychiatry With more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) disorders. In 2013 we launched Oxtellar XR® and Trokendi XR®, two novel neurology products for the treatment of epilepsy. We are also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder (ADHD) and its coexisting disorders, and depression. We are developing differentiated products by leveraging our proprietary and in-licensed technologies. We use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. Our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.
Company growth
Type
Public
HQ
Rockville, US
Founded
2005
Size (employees)
344 (est)+12%
Supernus Pharmaceuticals was founded in 2005 and is headquartered in Rockville, US

Key People at Supernus Pharmaceuticals

Jack A. Khattar

Jack A. Khattar

President and CEO

Supernus Pharmaceuticals Office Locations

Supernus Pharmaceuticals has office in Rockville
Rockville, US

Supernus Pharmaceuticals Metrics

Supernus Pharmaceuticals Summary

Market capitalization

$1.27 B

Closing share price

$25.1
Supernus Pharmaceuticals's current market capitalization is $1.27 B.

Supernus Pharmaceuticals Financials

Supernus Pharmaceuticals's revenue is $144 M in FY, 2015 which is a 18.34% increase from the previous period.
FY, 2015FY, 2014FY, 2013

Revenue

$144 M$122 M$12 M

Revenue growth, %

18.3%915.4%

Gross profit

$136 M$116 M$10.9 M

Operating income

$17.7 M$24.2 M$-61.9 M

Operating expense total

$118 M$92.1 M$72.8 M

Net Income

$14 M$19.9 M$-92.3 M

Operating cash flow

$-2.24 M$3.42 M$-7.32 M

Supernus Pharmaceuticals Market Value History

Supernus Pharmaceuticals Company Life

You may also be interested in